Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II longitudinal trial of PI-2620 in patients with mild cognitive impairment (MCI) and mild to moderate Alzheimer's-disease

Trial Profile

Phase II longitudinal trial of PI-2620 in patients with mild cognitive impairment (MCI) and mild to moderate Alzheimer's-disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PI 2620 (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Diagnostic use
  • Most Recent Events

    • 24 Sep 2019 New trial record
    • 17 Sep 2019 According to an AC Immune media release, data from this trial is intended to be used for obtaining regulatory approval in the U.S. and Europe.
    • 17 Sep 2019 According to an AC Immune media release, it has received a milestone payment from its partner Life Molecular Imaging in connection with the initiation of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top